Evidence map›Paper›PMID 24610926›Full record

SynthesisJournal of the American Society of Nephrology : JASN2014

Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy.

Elion Hoxha, Ina Thiele, Gunther Zahner, Ulf Panzer, Sigrid Harendza, Rolf A K Stahl

Registry-linked trialOpen access · bronzeAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of the American Society of Nephrology : JASN, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03549663 (Random, Open, Control and Monocentric Clinical Research on Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy), which is not on this map. Cited by 170 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
170citing papers in PubMed, 5 pooled it
19.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03549663 naunknown statusnot on this mapstarted 2018, after this paper: background citation

Random, Open, Control and Monocentric Clinical Research on Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy (IMN)

TypeinterventionalSponsorXinhua Hospital, Shanghai Jiao Tong University School of MedicineRan2018 to 2021Enrolled108ConditionsIdiopathic Membranous NephropathyArmsTacrolimus, Prednisone
3 · Its place in the literature

Who cites it

170 citing papers in PubMed, 5 syntheses or guidelines pooled it, 344 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy.Clinical journal of the American Society of Nephrology : CJASN · 2019
    Trial
  8. Trial
  9. Trial
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. [Primary glomerulonephritides].Innere Medizin (Heidelberg, Germany) · 2026
    Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

110 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Elion HoxhaUniversity Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Ina ThieleUniversity Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Gunther ZahnerUniversity Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Ulf PanzerUniversity Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Sigrid HarendzaUniversity Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Rolf A K StahlUniversity Medical Center Hamburg-Eppendorf, Hamburg, Germany rstahl@uke.de.
Universität Hamburg · DEUniversity Medical Center Hamburg-Eppendorf · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Membranous nephropathy (MN) is the most common cause of nephrotic syndrome in adults, with an uncertain clinical outcome. The characterization of the phospholipase A2 receptor (PLA2R) as the major target antigen in primary MN and the detection of circulating autoantibodies in these patients is a major advance in understanding this disease. To test whether PLA2R antibody levels reflect disease activity or clinical outcome, we performed a prospective multicenter study of 133 adult patients with primary MN and detectable serum PLA2R antibodies who had not received immunosuppressive therapy. Patients were followed ≤24 months. PLA2R antibody levels associated with clinical disease activity (proteinuria) in patients with immunosuppressive therapy (n=101) or supportive care (n=32). Within 3 months, immunosuppressive therapy led to a sustained 81% reduction in PLA2R antibody levels paralleled by a 39% reduction in proteinuria. Patients who experienced remission of proteinuria after 12 months had significantly lower PLA2R antibody levels at the time of study inclusion compared with patients with no remission. Patients with high PLA2R antibody levels achieved remission of proteinuria significantly later than patients with low PLA2R antibody levels. PLA2R antibody levels fell over time in patients with spontaneous remission but remained elevated in patients who did not show a reduction in proteinuria. Multivariable Cox regression analysis confirmed PLA2R antibody level as an independent risk factor for not achieving remission of proteinuria. We conclude that a decrease in PLA2R antibody level is associated with a decrease of proteinuria in patients with primary MN.

Indexed as

AdultAgedAutoantibodiesFemaleFollow-Up StudiesGlomerulonephritis, MembranousHumansImmunosuppressive AgentsMaleMiddle AgedNephrotic SyndromePrognosisProspective StudiesProteinuriaReceptors, Phospholipase A2Risk FactorsAutoantibodiesImmunosuppressive AgentsPLA2R1 protein, humanReceptors, Phospholipase A2Serum Albumin

Identifiers

PMID24610926
PMCPMC4033365
OpenAlexW2097148864

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.